子宫癌和卵巢癌的分子成像与精准医学

Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.

作者信息

Zukotynski Katherine A, Kim Chun K

机构信息

Division of Nuclear Medicine and Molecular Imaging, Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario L8S 4L8, Canada; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, McMaster University, 1200 Main Street West, Hamilton, Ontario L8S 4L8, Canada.

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02492, USA.

出版信息

PET Clin. 2017 Oct;12(4):393-405. doi: 10.1016/j.cpet.2017.05.007. Epub 2017 Jul 19.

DOI:10.1016/j.cpet.2017.05.007

PMID:28867111

Abstract

Gynecologic cancer is a heterogeneous group of diseases both functionally and morphologically. Today, PET coupled with computed tomography (PET/CT) or PET/MR imaging play a central role in the precision medicine algorithm of patients with gynecologic malignancy. In particular, PET/CT and PET/MR imaging are molecular imaging techniques that not only are useful tools for initial staging and restaging but provide anatomofunctional insight and can serve as predictive and prognostic biomarkers of response in patients with gynecologic malignancy.

摘要

妇科癌症在功能和形态学上是一组异质性疾病。如今，正电子发射断层显像（PET）与计算机断层扫描（PET/CT）或PET/MR成像在妇科恶性肿瘤患者的精准医疗算法中发挥着核心作用。特别是，PET/CT和PET/MR成像是分子成像技术，它们不仅是初始分期和再分期的有用工具，还能提供解剖功能方面的见解，并且可作为妇科恶性肿瘤患者反应的预测和预后生物标志物。